Advertisement

Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response

  • Li Li
  • Li Ma
  • Dongping Shang
  • Zhiguo Liu
  • Qingxi Yu
  • Suzhen Wang
  • Xuepeng Teng
  • Qiang Zhang
  • Xudong Hu
  • Wei Zhao
  • Wenhong Hou
  • Jianyue Jin
  • Feng-Ming (Spring) Kong
  • Jinming Yu
  • Shuanghu YuanEmail author
Original Article

Abstract

Purpose

To explore the relationship between metabolic uptake of the 18F-ALF-NOTA-PRGD2 (18F-RGD) tracer on positron emission tomography/computerized tomography (PET/CT) and the antiangiogenic effect of apatinib in patients with solid malignancies.

Materials and patients

Patients with measurable lesions scheduled for second- or third-line single-agent therapy with apatinib were eligible for this prospective clinical trial. All patients underwent 18F-RGD PET/CT examination before the start of treatment. Standardized uptake values (SUVs) of contoured tumor lesions were computed and compared using independent sample t-tests or the Mann–Whitney U test. Receiver-operating characteristic (ROC) curve analysis was used to determine accuracy in predicting response. Survival curves were compared using the Kaplan–Meier method.

Results

Of 38 patients who consented to study participation, 25 patients with 42 measurable lesions met the criteria for inclusion in this response assessment analysis. The median follow-up time was 3 months (range, 1–10 months), and the median progression-free survival (PFS) was 3 months (95% confidence interval, 1.04–4.96). The SUVpeak and SUVmean were significantly higher in responding tumors than in non-responding tumors (4.98 ± 2.34 vs 3.59 ± 1.44, p = 0.048; 3.71 ± 1.15 vs 2.95 ± 0.49, P = 0.036). SUVmax did not differ between responding tumors and non-responding tumors (6.58 ± 3.33 vs 4.74 ± 1.83, P = 0.078). An exploratory ROC curve analysis indicated that SUVmean [area under the ROC curve (AUC) = 0.700] was a better parameter than SUVpeak (AUC = 0.689) for predicting response. Using a threshold value of 3.82, high SUVmean at baseline was associated with improved PFS (5.0 vs. 3.4 months, log-rank P = 0.036).

Conclusion

18F-RGD uptake on PET/CT imaging pretreatment may predict the response to antiangiogenic therapy, with higher 18F-RGD uptake in tumors predicting a better response to apatinib therapy.

Keywords

Antiangiogenic therapy Malignancies 18F-RGD PET/CT Integrin αvβ3 

Notes

Acknowledgments

The authors would like to thank Ms. Laney Weber for excellent assistance.

Funding

This study was partially funded by Shandong Key Research and Development Plan (2017CXGC1209 and 2017GSF18164) and the Outstanding Youth Natural Science Foundation of Shandong Province (JQ201423), Jinan Clinical Medicine Science and Technology Innovation Plan (201704095), NSFC81372413, National Key Research and Development Program of China (2016YFC0904700).

Compliance with ethical standards

Conflict of interest

The authors declare no potential conflicts of interest.

Ethical standards

Our investigation was approved by the Shandong Cancer Hospital affiliated to Shandong University Ethical Committee. All persons gave their informed consent prior to their inclusion in the study.

References

  1. 1.
    Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65–71.Google Scholar
  2. 2.
    Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol. 2007;60:151–70.CrossRefGoogle Scholar
  3. 3.
    Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going. Br J Cancer. 2004;90:1–7.CrossRefGoogle Scholar
  4. 4.
    Abdelrahim M, Konduri S, Basha R, Philip PA, Baker CH. Angiogenesis: an update and potential drug approaches (review). Int J Oncol. 2010;36:5–18.Google Scholar
  5. 5.
    U.S. National Library of Medicine (2009–2012) Efficacy study of [F-18]RGD-K5 positron emission tomography (PET) as a tool to monitor response to an anti-angiogenic drug. ClinicalTrials.gov Identifier: NCT00988936. Sponsor: Siemens Molecular ImagingGoogle Scholar
  6. 6.
    Winick J (2007 A proof-of-concept study to assess the ability of [18F]AH- 111585 PET imaging to detect tumours and angiogenesis. ClinicalTrials.gov; November 28, 2007 ed. US: National Institutes of Health; 2007.Google Scholar
  7. 7.
    Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer. Science. 2006;312:1171–5.CrossRefGoogle Scholar
  8. 8.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefGoogle Scholar
  9. 9.
    Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2:83–90.CrossRefGoogle Scholar
  10. 10.
    Liu Z, Wang F, Chen X. Integrin alpha(v)beta(3)-targeted cancer therapy. Drug Dev Res. 2008;69:329–39.CrossRefGoogle Scholar
  11. 11.
    Danhier F, Le BA, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9:2961–73.CrossRefGoogle Scholar
  12. 12.
    Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med. 2006;47:763–9.Google Scholar
  13. 13.
    Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science. 2002;296:151–5.CrossRefGoogle Scholar
  14. 14.
    Yu YP, Wang Q, Liu YC, Xie Y. Molecular basis for the targeted binding of RGD-containing peptide to integrin alphaVbeta3. Biomaterials. 2014;35:1667–75.CrossRefGoogle Scholar
  15. 15.
    Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691–8.CrossRefGoogle Scholar
  16. 16.
    Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014;2:123.Google Scholar
  17. 17.
    Luan X, Huang Y, Gao S, Sun X, Wang S, Ma L, et al. (18)F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2016;43:2336–42.CrossRefGoogle Scholar
  18. 18.
    Shi J, Jin Z, Liu X, Fan D, Sun Y, Zhao H, et al. PET imaging of neovascularization with (68)Ga-3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy. Mol Pharm. 2014;11:3915–22.CrossRefGoogle Scholar
  19. 19.
    Bao X, Wang MW, Luo JM, Wang SY, Zhang YP, Zhang YJ. Optimization of early response monitoring and prediction of cancer antiangiogenesis therapy via noninvasive PET molecular imaging strategies of multifactorial bioparameters. Theranostics. 2016;6:2084–98.CrossRefGoogle Scholar
  20. 20.
    Yang G, Nie P, Kong Y, Sun H, Hou G, Han J. MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice. Tumour Biol. 2015;36:3285–91.CrossRefGoogle Scholar
  21. 21.
    Yang M, Gao H, Yan Y, Sun X, Chen K, Quan Q, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging. 2011;38:1237–47.CrossRefGoogle Scholar
  22. 22.
    Ji S, Zheng Y, Shao G, Zhou Y, Liu S. Integrin alpha(v)beta(3)-targeted radiotracer (99m)Tc-3P-RGD(2) useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin alpha(v)beta(3) RGD(2) therapy. Theranostics. 2013;3:816–30.CrossRefGoogle Scholar
  23. 23.
    Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, et al. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 2016;43:1047–55.CrossRefGoogle Scholar
  24. 24.
    Strieth S, Eichhorn ME, Sutter A, Jonczyk A, Berghaus A, Dellian M. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer. 2006;119:423–31.CrossRefGoogle Scholar
  25. 25.
    Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157–64.CrossRefGoogle Scholar
  26. 26.
    Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569–71.CrossRefGoogle Scholar
  27. 27.
    Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4:123–31.CrossRefGoogle Scholar
  28. 28.
    Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155:459–70.CrossRefGoogle Scholar
  29. 29.
    Zhang H, Liu N, Gao S, Hu X, Zhao W, Tao R, et al. Can an (1)(8)F-ALF-NOTA-PRGD2 PET/CT scan predict treatment sensitivity to concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? J Nucl Med. 2016;57:524–9.CrossRefGoogle Scholar
  30. 30.
    Niu G, Chen X. RGD PET: from lesion detection to therapy response monitoring. J Nucl Med. 2016;57:501–2.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Li Li
    • 1
    • 2
  • Li Ma
    • 2
  • Dongping Shang
    • 2
  • Zhiguo Liu
    • 2
  • Qingxi Yu
    • 2
  • Suzhen Wang
    • 2
  • Xuepeng Teng
    • 2
  • Qiang Zhang
    • 3
  • Xudong Hu
    • 2
    • 4
  • Wei Zhao
    • 2
  • Wenhong Hou
    • 2
  • Jianyue Jin
    • 5
  • Feng-Ming (Spring) Kong
    • 6
  • Jinming Yu
    • 2
  • Shuanghu Yuan
    • 2
    • 4
    Email author
  1. 1.School of Medicine and Life SciencesUniversity of Jinan–Shandong Academy of Medical SciencesJinanChina
  2. 2.Department of Radiation OncologyShandong Cancer Hospital and Institute–Shandong Cancer Hospital Affiliated to Shandong UniversityJinanChina
  3. 3.Zibo Forth People’s HospitalZiboChina
  4. 4.Shandong Academy of Medical SciencesJinanChina
  5. 5.Department of Radiation OncologyIndiana University School of MedicineIndianapolisUSA
  6. 6.Department of Radiation Oncology, Simon Cancer CenterIndiana University School of MedicineIndianapolisUSA

Personalised recommendations